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INTRODUCTION
Zinc is recognised as an important micronutrient [1, 2] . At least 10% of all human proteins require a structural or catalytic zinc cofactor [3] . In addition, zinc acts as an intracellular and extracellular signalling agent [4] . In consequence, zinc is involved in virtually every conceivable biological process, and thus the organismal zinc status affects for example, growth and development, the immune system, mental health, as well as cardiac health. It must also be noted that zinc, as the free Zn 2+ aquo-ion, is toxic to cells at very low concentrations [5] . Given its ubiquity, essentiality and potential cell toxicity, cellular zinc homeostasis [6, 7] is usually well-controlled, involving no less than 24 membrane-bound transporters of the ZIP and ZnT families [8] , and at least 13 expressed metallothioneins [9] . Alterations in zinc homeostasis are known to occur with increasing age [10] , and in some of the most prevalent diseases [11] , including neurodegenerative diseases, cancer, diabetes and cardiovascular disease (CVD) [12] . In many cases, it has remained obscure whether these alterations are cause or consequence, or both, of the respective disease state, and occasionally, it is even unclear whether the observed alterations are harmful or beneficial.
Mammalian zinc homeostasis on the organismal level also involves the circulatory system [13] . Although zinc plasma levels (reference values are around 16.6±6.2 µM [14] ) are affected by a range of conditions ( [15] , also see section 4), they are not decreased by mild zinc deficiency [16] . This suggests that plasma zinc levels are also subject to tight control -and it is important to understand how this control works. Apart from the crucial importance of ZIP and ZnT transporters, it is conceivable that this is also influenced by Zn 2+ binding to components of plasma -and chief amongst these is serum albumin [17] . Our studies have revealed that albumin directly links plasma zinc and free fatty acid (FFA) dynamics through allosteric binding. In the present review, we will explore how this allosteric link may impact on cardiovascular health and disease. Our findings also have direct implications for the diagnostics of myocardial ischemia through the biomarker "ischemiamodified albumin" (IMA), and since there is much confusion in the current literature regarding this, we will begin with a summary of the current state of the art on metal ion-albumin interactions.
The latter is only relevant for very thiophilic xenobiotic metal ions such as Au + [27], Pt 2+ [28] and Hg 2+ [29] , whereas the former three sites are capable of binding a range of 3d metal ions including Cu 2+ , Ni 2+ , Co 2+ , Mn 2+ and Zn 2+ .
These divalent metal ions and Cd 2+ display different preferences for the ATCUN site, site A and site B. Taking advantage of the Jahn-Teller effect, the d 8 and d 9 ions Ni 2+ and Cu 2+ show a distinct preference for the square-planar geometry provided by the ATCUN motif [22, 30, 31] . This binding mode involves the unprotonated terminal amino group and the imidazole side-chain of His3, and requires the deprotonation of two backbone amides. Both Cu 2+ and Ni
2+
can elicit this deprotonation at physiological pH, but Zn
and Co 2+ require a much higher pH to effect significant binding to model peptides [32] . Instead, the closed-shell Zn 2+ ion prefers the distorted site A [23, 24, 33] (dissociation constant K D = 0.3-40 µM [34] [35] [36] [37] ), and the highest affinity site for Co 2+ (high-spin d 7 ) has been determined as site B (K D = 11 µM [38] ), followed by site A (90 µM) and, lastly, ATCUN (110 µM) [38] . Cu 2+ binds with picomolar affinity to the ATCUN site [31] , and with a K D = 10 nM to site A [39] . The respective values for Ni 2+ are 150 nM [40] and 12.5 µM [41] .
Site A has also been termed the multi-metal binding site (MBS) [39, 41] : whilst it is a primary site for Zn 2+ and Cd 2+ , it is a secondary site for Cu 2+ , Ni 2+ and also Co 2+ . This means that whenever more than one equivalent of the latter ions are added to pure, ligand-and metal-free albumin, this site will become significantly occupied by the respective metal ion. It is also important to note that in human and bovine serum albumin (HSA and BSA), Cu 2+ still forms stronger interactions with this site than either Cd 2+ , Ni 2+ Co 2+ , or Zn 2+ [40] . This is in keeping with expectations based on the Irving-Williams series, which describes the order of affinities of divalent high-spin complexes [42] .
The location [33] and structure [43] of the major zinc site (and hence the secondary site for Co 2+ , Ni 2+ , and Cu
) have been determined using a range of spectroscopic techniques, although no X-ray crystallographic studies on any Znalbumin complexes are as yet available. The most striking peculiarity of this site is its location at the domain interface between domain I and domain II of HSA (Figures 1a and b) . It is formed by two residues from each domain: His67 and Asn99 from domain I and His247 and Asp249 from domain II. These four residues are conserved in albumins from mammals. A copious amount of X-ray crystallographic studies have been carried out on HSA [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] , with structural information on other serum albumins having become available recently [54, 55] . Inspection of these structures reveals that the MBS is consistently only present in fatty acid-free preparations [33] (Figure 1c ). Fatty acids are the primary ligands for albumin, and albumin is the primary plasma transporter for long-chain unesterified (or "free") fatty acids (FFA), which are the primary source of energy for the myocardium. The origin of disruption of the MBS is traceable to the FFA binding site FA2 [46] , which significantly also requires interacting residues from both domains I and II (Figure 1d ). Although there is no overlap between the zinc-and fatty-acid binding residues, the domain-domain movement that is required to form the FFA binding pocket essentially leads to the destruction of the preformed zinc-binding site [33] . This observation raised the question whether zinc binding inhibited fatty acid binding to this site, or vice versa. Isothermal titration calorimetry (ITC) studies involving the ternary system BSA, Zn 2+ and myristate clearly demonstrated that the C14 fatty acid inhibited zinc binding to albumin (Figure 2d ) [37] . Recent studies confirmed that fatty acids inhibit zinc binding to the MBS also in HSA (Figure 2a ) [56] .
This allosteric switch is expected to have multiple physiological consequences, further described in sections 3 and 4. Under normal conditions, between 0.1 and 2 FFA molecules are carried per albumin molecule [19, 57] , but there a number of conditions, including fasting, extreme exercise [58] , obesity, metabolic syndrome, diabetes mellitus, and cardiovascular disease [59] including atherosclerosis and myocardial infarction [60] , under which up to four [19] , or even more [61] , FFA molecules can become bound. Importantly, many of these conditions are also associated with considerable shifts in plasma zinc levels, and these observations, together with our structural and thermodynamic studies, have led us to hypothesise that these correlations are mediated by HSA [15] -the main transporter for both zinc and FFAs in plasma. However, it should be stressed that FFA effects on zinc speciation and distribution are not expected to be restricted to such drastic conditions -we observed marked differences in zinc affinity and binding capacity even at just 1 molar equivalent of myristate for both BSA and HSA (Figures 2a and b) [37, 56] . This is consistent with observations by the group of Hamilton that indicated that FA2 is one of the highestaffinity FFA binding sites on HSA [62, 63] .
One further momentous implication of this allosteric switch is based on the fact that MBS is, as mentioned earlier, also a secondary binding site for other M 2+ metal ions. This simply means that the Co 2+ (and Cu 2+ and Ni 2+ ) binding capacity and affinity of albumin will also be affected by fatty acid levels, and for Co 2+ , this has indeed been demonstrated (Figure 2e ). Myocardial ischemia is one of the many conditions in which FFA levels are significantly elevated. Hence, the FFA-mediated allosteric switch also effortlessly explains the reduction in metal binding in diagnostic tests related to the Albumin-Cobalt-Binding (ACB) test [64, 65] , as well as the identity of the elusive biomarker "IschemiaModified Albumin" (IMA): IMA is simply albumin with a higher ratio of FFA bound. The case for this assertion, as well as ensuing implications, will be laid out in section 5.
FFA-mediated alterations in plasma zinc speciation: Implications for neutralisation of heparins
Zinc is an important regulator of coagulation following its release from activated platelets [66] . The resultant local increases in Zn 2+ concentration are sensed by a range of haemostatic proteins to stimulate a pro-coagulatory response [67] ; this represents an essential transition phase that promotes the propagation of coagulation. Plasma proteins that bind Zn 2+ under these conditions include histidine-rich glycoprotein (HRG), a key effector molecule upon which Zn 2+ acts to regulate coagulation [68, 69] . HRG is a 75 kDa glycoprotein present at a concentration of 1.3-2.0 μM in adult blood [69, 70] . [43] and fatty-acid binding site FA2 (d) [46] . The three domains of albumin are shown in grey (domains I and III) and black (domain II). (b) shows a close-up of the distorted 5+1 metal binding site; the backbone carbonyl oxygen of His247 also forms a long bond to the Zn 2+ ion. In (d), the four zinc-binding residues are shown with thin lines, and some residues forming the two halves of the FA2 binding pocket are shown as sticks, with the resolved part of a myristate molecule shown in space-filling mode. (c) MBS residues in a selection of X-ray structures with and without (pdb 4G03, 2BXH, 4F5V (rabbit SA), 3V09 (rabbit SA), 3JRY, 1E78, 1AO6, 4K71 (HSA in complex with the Fc receptor) [45, 50, 51, 53, 54, 55] ) bound fatty acids (decanoate (1E7E), dodecanoate (1E7F), myristate (3SQJ, 1E7G), palmitate (1E7H), stearate (1E7I), oleate (1GNI), arachidonate (1GNJ) [47, 48] ). The overlay was generated by aligning the backbone atoms of residues His247, Gly248, and Asp249 in Swiss pdb viewer v. 3.7.
We recently demonstrated that HRG possesses ten Zn 2+ sites (with an average apparent K d of ~6 μM) and that Zn 2+ -binding enhances the ability of HRG to bind and neutralize long-chain heparins [56] . Under normal conditions heparin binds to and stabilizes the anticoagulatory antithrombin III/thrombin complex. During clotting, thrombin cleaves fibrinogen into insoluble strands (fibrin) that are cross-linked by factor XIII to form a blood clot [71] . Zn 2+ -dependent neutralization of heparin by HRG provides increased competition for heparin binding to this complex, which may result in release of thrombin and an increase in its activity, which will ultimately promote clotting.
Speciation modelling experiments based upon affinity and stoichiometry data for Zn 2+ -binding to HRG and to albumin (in the absence and presence of various concentrations of myristate) suggested that the FFAmediated reduction in availability of the MBS increases the proportion of plasma Zn 2+ bound to HRG (Figure 2c ), such that its ability to neutralize heparins will be increased [56] . However, it is important to point out that this simple model only considered serum albumin and HRG and did not take into account other circulatory proteins that could bind displaced Zn 2+ . These include other components of the blood-clotting cascade [67] , as well as numerous components of the immune system [72] . It is also important to point out that HRG can also associate with molecules other than heparin (such as tropomyosin, factor XIIa and soluble IgG) in a Zn 2+ -dependent manner [69, 73] , thus the actions of increased Zn 2+ -binding to HRG are likely to be complex.
Interestingly, a recent study by Fredenburgh et al. has revealed that fibrinogen, like HRG, also binds heparin with high affinity in a Zn 2+ -dependent manner [74] . Fibrinogen is a glycoprotein present in plasma at a concentration of around 6-12 μM [71, 75] . The study by Fredenburgh et range; values of 9.4 μM and 4.5 μM were measured using surface plasmon resonance and a fluorescence-based assay, respectively. Furthermore, they found that Zn 2+ promotes a 4-fold increase in heparin binding to fibrinogen. This study highlights the fact that Zn 2+ can potentially influence heparin neutralization by fibrinogen as well as by HRG. Also a further reduction of heparin activity will occur when fibrinogen is clotted because heparin promotes thrombin binding to fibrin and induces the formation of a complex that limits inhibition by antithrombin [76, 77] . Zinc also stimulates platelet aggregation by promoting fibrinogen binding to α IIb β 3 , its cognate receptor on the platelet surface [66, 78] .
The observations above are particularly interesting as disorders characterized by chronically elevated levels of plasma fatty acids are associated with an increased risk of thrombosis [79, 80] . These include obesity [81, 82] , diabetes [83] , fatty liver disease [84] , and cancer [85] . For example, thromboembolism (caused by obstructive blood clots) is the second leading cause of death associated with malignancy [79] . Collectively, these observations suggest that under conditions where FFA levels are elevated, Zn 2+ displaced from serum albumin could bind HRG or fibrinogen to enhance their respective interactions with heparins and induce a pro-coagulatory effect [86] , as summarized in Figure 3 . In older adults, this may be further compounded as plasma albumin levels are known to decrease with age [87] . An age-related decrease in plasma albumin also correlates with an observable increase in the ratio of FFAs per albumin molecule [88] . It is important to point out that the degree to which each of the respective proteins, HRG and fibrinogen, contribute to Zn 2+ -dependent neutralization of heparins remains to be determined. However, evidence for a direct link between defective plasma Zn 2+ -handling, mediated by FFA-displacement of Zn 2+ from albumin, and thrombotic risk is compelling. [37, 56] . (b) and (c) Plasma speciation modelling suggested that the reduction in binding site availability may result in an increase of free Zn 2+ and zinc bound to HRG [56] . (e) ITC experiments revealed a similar reduction of overall binding site availability for Co 2+ [149] . One out of three possible binding sites is lost in the presence of 5 mol. equiv. of myristate. ND indicates that no data is available. (f) Myristate binding to BSA leads to increased Co-DTT complex formation in the ACB assay [149] . The line is drawn to guide the eye and does not represent a fit. 
Cellular effects of altered plasma zinc speciation and cardiovascular disease
A number of studies have examined the association of zinc with coronary diseases, cardiomyopathies and arrhythmias, and links between etiopathogenesis of CVD have been suggested [89] [90] [91] . Aberrant Zn 2+ -homeostasis is associated with cardiomyopathy including chronic heart failure and myocardial damage [11, 89] , as well as primary arterial hypertension [92, 93] . Many intracellular enzymes and other proteins involved in regulating cardiac function are Zn 2+ -dependent [89] ; furthermore, zinc homeostasis and intracellular redox balance are intimately linked [6, 94] . Therefore, the impact of zinc on cardiovascular health is most probably multifactorial; some potential mechanisms and pathways are discussed in this section.
Potential impact of albumin on cellular zinc homeostasis
Intracellular zinc concentrations are known to be regulated largely by zinc transporters, zinc binding proteins including metallothioneins, and zinc sensors [6, 7] , but the extracellular space also participates in zinc dynamics. Indeed, various studies have suggested that serum albumin helps to regulate the uptake of Zn 2+ by a range of cell types. For example, serum albumin facilitates the uptake of Zn 2+ into endothelial cells [95] and erythrocytes [96] . Also receptor-mediated vesicular co-transport of Zn 2+ with albumin across the endothelium has been demonstrated in vitro [97] . Despite this, any direct role for albumin in mediating delivery of Zn 2+ to cells via endocytosis is likely to be relatively minor as only~2% of circulating albumin molecules carry Zn 2+ at any one time. The primary function of albumin in mediating Zn 2+ uptake is through maintenance of the plasma exchangeable zinc pool. Ultimately, Zn 2+ will cross cell membranes predominantly through ZIP (transport from plasma into cells) and ZnT (transport into plasma) transporters. Crucially, the activity of these transporters depends on availability of free Zn 2+ -and this in turn is regulated by the assortment of molecules that can reversibly bind Zn 2+ in plasma. If the zinc-binding capacity of plasma drops, this may lead to an increase in free Zn 2+ (Figure 2b ), which should, in the first instance, result in increased cellular uptake. This may manifest in decreased levels of plasma zinc. Intriguingly, the same conditions that are associated with high FFA levels, including congestive heart failure, myocardial ischemia and infarction, are also known to result in decreased plasma zinc [98, 99] -more precisely, exchangeable, albumin-bound zinc [100, 101] . This is consistent with the idea that in these conditions, the increased FFA levels lead to lower zinc-binding capacity by albumin, and an increase in free Zn 2+ available for cellular uptake. We hypothesise that conditions that lead to elevated plasma FFA might cause significant changes to cellular zinc homeostasis, at the very least in cells in direct contact with plasma, including erythrocytes, platelets, macrophages, Band T-cells, endothelial cells, but potentially also vascular smooth muscle cells (VSMC) and cardiomyocytes. Based on the facts that both a lack of zinc [102] as well as excessive extracellular free Zn 2+ [5] has deleterious effects on cells in general, any large perturbation of plasma zinc homeostasis may be expected to have direct or indirect detrimental consequences for cells. Some possible effects are described below.
Effects of zinc on intracellular calcium signalling in cardiomyocytes

Ca
2+
is crucially involved in the function of cardiomyocytes and VSMCs [103] , with intracellular Ca 2+ release from the sarcoplasmatic reticulum through ryanodine receptors triggering the contraction of these muscle cells [104] . CVD has been linked to dysregulated intracellular Ca 2+ release, reduced cardiac contractility and prolonged rises of systolic Ca 2+ [105] . There is cross-talk between the fluxes of Ca 2+ and Zn 2+ [106] ; hence, it is thought that zinc dyshomeostasis will impact on Ca 2+ trafficking in cardiomyocytes (as recently reviewed in [107] ). Various studies suggest that defective Zn 2+ handling contributes to cardiomyopathies including altered contractility and heart failure [89, [108] [109] [110] . Indeed, it has been hypothesised that increased cytosolic Zn 2+ can influence cardiac excitationcontraction coupling through regulation of the ryanodine receptor in cardiomyocytes [111, 112] . The combined effects of Zn 2+ and Ca 2+ dyshomeostasis are also thought to generate oxidative stress, lead to cardiac myocyte necrosis and replacement fibrosis [113] .
Blood pressure effects of zinc
Changes of both intracellular and extracellular zinc contents have been documented for primary arterial hypertension [92, 93] . Serum zinc levels are decreased in arterial hypertension, as are those in lymphocytes and bone, whereas zinc levels in erythrocytes, heart, liver, kidney and various glands are increased; overall, the organism becomes zinc-deficient. It has remained unclear whether this systemic zinc dyshomeostasis is cause or consequence of arterial hypertension. Lower plasma zinc levels are suggested to impact on Ca 2+ fluxes, and the activities of angiotensinconverting enzyme (ACE), endothelin-converting enzyme, and neutral endopeptidase. Increased erythrocyte zinc is associated with increased carbonic anhydrase activity, which may result in increased blood pH. Angiotensins are vasoconstrictors; thus a decrease in ACE activity leads to increased levels of angiotensins and hence increased blood pressure. Also endothelial NO-synthase (eNOS) is involved in the generation of the vasodilator NO, hence important for the regulation of blood pressure. eNOS contains a structural zinc site that is essential for enzyme function; its disruption by reactive oxygen and nitrogen species has been demonstrated [114] . Thus, zinc dyshomeostasis may either directly or indirectly affect its activity, with a lack of zinc expected to lead to decreased NO levels and hence increased blood pressure.
Zinc dyshomeostasis in atherosclerosis
The major underlying mechanism in the development of CVD is the formation of atherosclerotic plaques in the wall of blood vessel which eventually leads to stroke, heart attack and lower limb disease [115, 116] . There is much evidence that zinc deficiency is pro-atherogenic [117] . A number of pathways have been invoked to explain this correlation, as summarized in Figure 4 . For example, inflammation is known to play a major role in the development of atherosclerosis [118] . Zinc has been shown to impact on several of the molecules that have been implicated in this etiology. For instance, the zinc-dependent [119] transcription factor NF-кB, a key element in regulation of inflammatory responses [120] may in many cells be regulated by Zn 2+ status [121] . NF-кB regulates amongst others the expression of vascular cell adhesion molecule (VCAM)-1, ICAM-1, Eselectin, cytokines of the interleukin family, plasminogen activator inhibitor (PAI)-1, and inducible nitric oxide synthase (iNOS). Cytokine transcription is also directly regulated by zinc [122] , and several cytokines (IL-β, IL8 and TNF-α) themselves induce expression of E-selectin, ICAM and VCAM. This results in trapping of monocytes, platelets, neutrophils and erythrocytes, which subsequently block blood vessels. Zinc also impacts on various other signalling networks, including those involving protein kinase C (PKC), which plays a central role in many signalling pathways in endothelial and vascular smooth muscle cells [123] . Thrombin, angiotensin and endothelin all trigger the activation of PKC, via signalling cascades involving Gprotein-coupled receptors and phospholipase C. The latter hydrolyses phospholipids, and the resulting diacylglycerols activate PKC [89, 124] . PKC contains a redox-sensitive zincbinding site, and it is thought that through this site, the cellular redox state regulates the activity of PKC [89] . The link between zinc and cellular redox state is well established [6] . PKC plays an important role in proteoglycan synthesis. Proteoglycans are components of the extracellular matrix. Their composition has been shown to be critical for lipid retention, and hence, atherosclerosis [125] . Thus, modulating PKC activity by Zn 2+ will in turn regulate various vasoactive factors that ultimately impact on the development of atherosclerosis. Another group of zinc-dependent enzymes critically involved in the extracellular matrix are the matrix metalloproteinases. They are implicated in the response to inflammation [126] , and regulate the bioavailability and activity of cytokines, chemokines, and growth factors. They degrade the extracellular matrix, cell surface components as well as intracellular proteins, and are therefore particularly important for vascular and cardiac tissue remodelling, both in normal conditions but also, e.g., during the development of atherosclerosis [127] and the adverse structural remodelling of the myocardium [128] . In atherosclerosis, they may either stabilise or promote rupture of plaques, and hence contribute to acute myocardial infarction [129] . Since they require a zinc cofactor, their activity may be modulated by zinc dyshomeostasis, although no detailed studies on this hypothesis are available.
In addition, a lack of zinc is associated with apoptosis in many cell types [130] . Endothelial cell injury and apoptosis is a defining event in atherosclerosis [131] , and it is thought that oxidative stress resulting from lipid peroxidation and the action of inflammatory cytokines is a major contributor to these processes [11] . Zinc has both anti-inflammatory and anti-oxidant effects [132] , and it has been suggested that Zn 2+ performs a crucial role in maintaining the integrity of endothelial cells [121] . Thus it is possible that chronically lower plasma levels contribute to endothelial cell apoptosis. In contrast, long-term zinc deprivation has also been shown to accelerate rat VSMC proliferation via down-regulation of the JNK1/2 pathway [133] . Accelerated VSMC proliferation is a contributing factor in development of atherosclerosis through thickening of the vascular wall [134] .
Finally, one may also consider the effects of increased free extracellular Zn 2+ . Although the anti-inflammatory function of dietary zinc has been mentioned, the direct action of Zn 2+ on vascular endothelial cells induces inflammation [135] . Induction of senescence by Zn 2+ of VSMCs has also been reported, and it is thought that this is mediated through angiotensin [136] . More drastically, cell survival of primary cultures of cardiomyocytes was negligible at only 0.6 µM free Zn 2+ [5] .
FFA-loading of albumin as the molecular basis of ischemia-modified albumin
Ischemia-modified albumin (IMA) is a biochemical marker of myocardial ischemia (MI) for the detection and the early diagnosis of acute coronary syndromes [137] . IMA can be measured using the albumin-cobalt-binding (ACB) assay, which was first established by Bar-Or et al. [138] . The ACB assay has a high negative prognostic value, which is useful in rapidly excluding ischemia as a cause of chest pain [65, 139] . Despite this, the specificity of the test is low, with increased IMA values also characteristic of various other conditions including fatty liver, cancer, infections, renal disease, preeclampsia, diabetes, stroke, and even sustained exercise [140] [141] [142] [143] [144] [145] .
The basic principle of this test is such that following an ischemic event, serum albumin is somehow chemically modified such that its ability to bind Co 2+ is compromised. As a quantitative analytical method, the ACB test is performed by the addition of CoCl 2 to a patient plasma sample, followed by the addition of dithiothreitol (DTT) to complex the portion of Co 2+ that has remained unbound to serum albumin, and finally detection of a brown color corresponding to formation of the Co-DTT complex [138] .
The molecular basis for IMA and what it exactly is has remained controversial. For some time it was incorrectly assumed that the primary Co 2+ binding site on albumin is at the N-terminus and that ischemia leads to the cleavage of the first two residues or some other oxidative modification such that this metal binding site is effectively removed [64, 146] . However, several efforts to prove a correlation between Nterminal modification and positive ACB assay have failed repeatedly [139, 146, 147] . Moreover, several in-vitro metal binding studies since 2007 concluded that the N-terminal ATCUN site is not the primary Co 2+ -binding site [38, 148, 149] .
Based on our identification of the location of MBS and its allosteric regulation by fatty acids [33] , Mothes and Faller hypothesised in 2007 that the reduced Co 2+ binding of IMA may be related to fatty-acid inhibition of Co 2+ binding to the MBS [148] . Soon after, based on the observation that plasma concentrations of FFAs rise during MI [150, 151] , a relationship between FFAs and the reversible generation of IMA was suggested [144] , and Bhagavan et al. found a "plausible but not causative relationship" between IMA levels and FFA levels in the sera of patients with acute myocardial infarction relative to controls, whereby an increase in FFA levels resulted in a lower Co 2+ -binding capacity, and hence an increase in IMA [60] . This explains why positive ACB tests are also found in a plethora disorders unrelated to MI, but which are associated with increased plasma concentrations of FFAs [141, 142, 144, 145] .
Crucially, plasma FFAs are predominantly bound to albumin in the circulation [152] . Based on our previous work where we demonstrated interactive binding of FFAs and Zn 2+ at the MBS [33, 37] , we examined the effects of FFAs on Co 2+ binding to albumin in vitro [149] . The results of this study revealed that physiologically relevant concentrations of the long chain FFA myristate were sufficient to reduce the Co 2+ -binding affinity and capacity of bovine serum albumin [149] , in a manner broadly similar to that of Zn 2+ [37] . Myristate binding to BSA was shown to inhibit metal binding to both sites A (MBS) and B [37, 149] (with the latter being the primary Co 2+ binding site [38] ), resulting in a decrease in total Co 2+ -binding site availability and a corresponding increase in Co-DTT complex formation in the ACB assay [149] (Figures 2e and 2f) . The results of this work, taken together with the already established link between elevated plasma FFA levels and MI [60, 144, 150, 151] , strongly suggest that IMA corresponds to albumin with increased levels of bound FFAs and not Nterminally modified albumin. These observations have important implications for the detection of MI as they suggest that "IMA" is strictly speaking neither a marker for ischemia nor oxidative stress, but a proxy measurement of plasma FFA levels.
Even though hypotheses based on permanent covalent modifications are incompatible with the rapid clearance of IMA within hours of the ischemic event -serum albumin has a circulating half-life of 19 days! -and even though a 2012 study by Oh et al. categorically stated an "Insignificant role of the N-terminal cobalt-binding site of albumin in the assessment of acute coronary syndrome" -and even though our own 2012 study had offered experimental evidence supporting a coherent molecular mechanism that is compatible with all clinical observations [149] , many researchers working in this area appear ignorant to this collective evidence, with a host of recent publications perpetuating the myth of N-terminal modification of albumin being the basis for the assay [153] [154] [155] . Very recently Eom et al., acknowledging that the N-terminus is not the primary Co 2+ binding site but still convinced that the N-terminus of IMA is modified, even attempted to improve the ACB assay through use of Cu 2+ (rather than Co 2+ ) [153] , which has been known for many years to bind strongly to albumin at the Nterminus [20, 22, 38, 39] . This new test was employed with success, as was a previous attempt by others to use binding of Ni 2+ (the first equivalent of which also binds at the Nterminus) as the basis of the assay [156] . In each case the metal ion (either Cu 2+ or Ni 2+ ) bound, like Co 2+ , less effectively to IMA than control albumin [153, 156] . However, the concept of Cu 2+ and Ni 2+ -binding to albumin also being influenced by FFA-loading is not surprising as 113 Cd-NMR and other spectroscopic studies previously revealed the multi-metal site to be a strong secondary binding site also for these metal ions following saturation of the N-terminal site [20, 39, 40] . Therefore, as long as the metal ion is added in excess over albumin, MBS will act as a sensor for plasma FFA for all three M 2+ mentioned. Indeed, in the original ACB assay, 140 µM Co 2+ and 90-100 µM albumin are present [138] . In the nickel-based test, there was a 3-fold excess of Ni over albumin [156] , whereas we were unable to establish the Cu:albumin ratio in the copper-based test. We also note that site B, the primary Co 2+ binding site, is also FFA-responsive in BSA [37, 149] ; whether this is also the case for HSA has not yet been established conclusively.
These observations are not meant to bring these important diagnostic tests into disrepute; our main motivation for this discussion is the desire that the molecular basis for the test be well and truly understood. IMA can be detected within minutes of an ischemic event, and remains the only marker for the early detection of MI. We strongly believe that metal-based tests detecting IMA are valuable and should have their place in modern clinical diagnosticsnot only in MI, but other diseases related to elevated plasma FFA. Indeed, a recent study has established that IMA is a better prognostic marker than other biomarkers for peripheral arterial occlusive disease [157] .
CONCLUSIONS
CVD represents colossal challenges due to its huge health burden on society. The importance of metals as dietary factors and essential inorganic micronutrients capable of modifying CVD has come to prominence only recently; hence, guidelines from the national heart associations at present are mostly silent on the relation between CVD and metal ions [89] . When the levels of circulatory trace metals in blood become depleted, nutrient metals absorbed from the diet are actively transported into blood and from there to cells as needed. However, abnormalities in the ratios and levels of trace metals will likely develop when this system fails. Although albumin chemistry is of undoubted importance in controlling the circulatory exchange of such metals (and other ligands), many features of its chemistry are yet to be fully understood. Here we have attempted to illustrate this by examining the interplay between the MBS and FFA binding to albumin. It is apparent that the interactive binding of Zn 2+ (and other metals that bind at this site) and long-chain fatty acids has potential physiological and clinical consequences. This is highlighted in the discovery that IMA represents FFA-loaded albumin and that the ACB assay is a proxy measurement of the FFA content of albumin. However despite this, further work is necessary to fully understand the physiological and pathological importance of elevated FFA levels and their impact on circulatory metal ion speciation. We envision that the work highlighted here will motivate others to examine causes and potential downstream effects of altered plasma metal ion speciation. It is hoped that such studies will enable us to better understand the molecular relationships that exist between the transport of metabolites and metal ions in plasma and their relevance to physiological and pathological processes.
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